SEC Form 4	
FORM 4	

[ ]

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ciaramella Giuseppe</u>					er Name <b>and</b> Ticker 1 Therapeutic					5. Relationship of Reporting Person(s) to Iss (Check all applicable)					
					•					Director	10% (				
(1.551)	(Einet)		3. Date of Earliest Transaction (Month/Day/Year)							Officer (give title Other below) below)		(specify )			
(Last) (First) (Middle)					2021		JIIII/D	ay/rear)		President & CSO					
C/O BEAM THERAPEUTICS INC.															
26 LANDSDOWNE STREET					andmont Data of (	Driginal	Filed	(Manth/Day/)/a	6 Indi	C. Individual on Jaint/Crown Siling (Chaol: Applicable					
(Chrant)				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CAMBRIDGE MA 02139										X	Form filed by One	e Reporting Pers	on		
	WIA	02133									Form filed by More than One Reporting				
(City)	(State)	(Zip)									Person				
(City)	(Oldic)	(21)													
		Table I - No	n-Deriva	ative S	ecurities Acq	uired,	Dis	posed of, o	r Bene	eficially	Owned				
Date			2. Transa Date (Month/D	Execution Date,		3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)		
Common Stock 03/0			03/05/	/2021		М		4,030	A	\$0.67	19,761	D			
Common Stock 03/31			/2021		A		25,000 <sup>(1)</sup>	A	\$0.00	44,761	D				
		Table II -			curities Acqui IIs, warrants, (			,		-	wned				

(e.g., puis, cans, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$0.67	03/05/2021		М			4,030	(2)	05/08/2028	Common Stock	4,030	\$0.00	265,414	D		
Stock Option (Right to Buy)	\$80.04	03/31/2021		A		50,000		(3)	03/31/2031	Common Stock	50,000	\$0.00	50,000	D		

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Company's 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Company through each vesting date.

2. 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares shall vest in 36 substantially equal monthly installments thereafter, subject to continued service with BEAM through such dates.

3. The stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with the Company through each vesting date.

Remarks:

By: Christine Bellon, Attorney-04/02/2021

<u>in-fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.